August 21, 2013
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn’s disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of…
October 8, 2015
…Provenance Biopharmaceuticals Corp., to “humanize” the antibody, modifying it so that it would be suitable for subsequent clinical work. Gillies also created the cell line for producing the pharmaceutical product that enabled clinical studies of the drug beginning in the late 1980s. “Drug development is a bit like a relay…
March 25, 2013
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.
May 13, 2013
Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system – a network of vessels that transports and stores immune cells throughout the body – to promote the spread of disease, a…
December 13, 2013
Researcher Thomas J. Kipps, MD, PhD, professor of medicine and deputy director of research operations at UC San Diego Moores Cancer Center, is principal investigator for one of six “Disease Team” awards approved December 12 by the governing board of the California Institute for Regenerative Medicine (CIRM).
August 21, 2019
University of California San Diego School of Medicine researchers identified a new therapeutic approach in mouse models that halts drug resistance and cancer progression by using an antibody that induces the immune system via macrophages to seek and kill cancer cells.
March 1, 2021
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
December 7, 2021
UC San Diego researchers identify new strategy to improve efficacy of immunotherapy on resistant liver cancers.
August 2, 2022
Researchers report that a gene therapy approach, developed at UC San Diego measurably delayed disease onset in humanized mouse and rat models of familial ALS, an inherited form of the disease that runs in families.
October 20, 2016
…for the benefit of humankind,” said Chancellor Pradeep K. Khosla. “Sally Ride will allow us to address our planet’s most pressing challenges and ensure that our oceans and atmosphere are preserved and protected for generations.” R/V Sally Ride is one of the world’s most technologically advanced ships. Features include dynamic…
